Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Targeted therapy combination reduced the risk of disease progression or death by 65% in a randomized study.
Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.
Imbruvica-based treatment may also work better than intensive chemotherapy for younger patients.
Venclexta plus Gazyva reduces risk of disease progression or death.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.